Skip to main navigation Skip to search Skip to main content

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

  • Jennifer J.G. Welch
  • , Cindy L. Schwartz
  • , Meghan Higman
  • , Lu Chen
  • , Allen Buxton
  • , Jennifer A. Kanakry
  • , Samir B. Kahwash
  • , Robert E. Hutchison
  • , Debra L. Friedman
  • , Richard F. Ambinder

Research output: Contribution to journal › Article › peer-review

Abstract

Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children’s Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.

Original languageEnglish
Pages (from-to)681-684
Number of pages4
JournalBlood Advances
Volume1
Issue number11
DOIs
StatePublished - Apr 25 2017

Fingerprint

Dive into the research topics of 'Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this